162 related articles for article (PubMed ID: 36680171)
1. Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe.
Kostaki EG; Mossialos E; Tseti I; Sfikakis PP; Paraskevis D
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680171
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).
Chrysostomou AC; Vrancken B; Haralambous C; Alexandrou M; Gregoriou I; Ioannides M; Ioannou C; Kalakouta O; Karagiannis C; Marcou M; Masia C; Mendris M; Papastergiou P; Patsalis PC; Pieridou D; Shammas C; Stylianou DC; Zinieri B; Lemey P; The Comessar Network ; Kostrikis LG
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766339
[TBL] [Abstract][Full Text] [Related]
3. Global Distribution, Dispersal Patterns, and Trend of Several Omicron Subvariants of SARS-CoV-2 across the Globe.
Kopsidas I; Karagiannidou S; Kostaki EG; Kousi D; Douka E; Sfikakis PP; Moustakidis S; Kokkotis C; Tsaopoulos D; Tseti I; Zaoutis T; Paraskevis D
Trop Med Infect Dis; 2022 Nov; 7(11):. PubMed ID: 36422924
[TBL] [Abstract][Full Text] [Related]
4. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
[TBL] [Abstract][Full Text] [Related]
5. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
Hossain A; Akter S; Rashid AA; Khair S; Alam ASMRU
Microb Pathog; 2022 Sep; 170():105699. PubMed ID: 35944840
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of novel SARS-CoV-2 rapid antigen tests in the era of omicron outbreak.
Widyasari K; Kim S
PLoS One; 2023; 18(8):e0289990. PubMed ID: 37561721
[TBL] [Abstract][Full Text] [Related]
7. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.
Sarkar A; Omar S; Alshareef A; Fanous K; Sarker S; Alroobi H; Zamir F; Yousef M; Zakaria D
Hum Vaccin Immunother; 2023 Dec; 19(1):2212568. PubMed ID: 37254497
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.
Li Y; Shen Y; Zhang Y; Yan R
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376697
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Xia S; Wang L; Jiao F; Yu X; Xu W; Huang Z; Li X; Wang Q; Zhu Y; Man Q; Jiang S; Lu L
Emerg Microbes Infect; 2023 Dec; 12(1):2178241. PubMed ID: 36748716
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro.
Zhang Y; Lv Q; Qi F; Li F; Deng R; Liang X; Liu M; Yan Y; Bao L
Animal Model Exp Med; 2023 Feb; 6(1):51-56. PubMed ID: 36808904
[TBL] [Abstract][Full Text] [Related]
12. Immune Evasion of SARS-CoV-2 Omicron Subvariants.
Ke H; Chang MR; Marasco WA
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146623
[TBL] [Abstract][Full Text] [Related]
13. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Kimura I; Yamasoba D; Tamura T; Nao N; Suzuki T; Oda Y; Mitoma S; Ito J; Nasser H; Zahradnik J; Uriu K; Fujita S; Kosugi Y; Wang L; Tsuda M; Kishimoto M; Ito H; Suzuki R; Shimizu R; Begum MM; Yoshimatsu K; Kimura KT; Sasaki J; Sasaki-Tabata K; Yamamoto Y; Nagamoto T; Kanamune J; Kobiyama K; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Shirakawa K; Takaori-Kondo A; Kuramochi J; Schreiber G; Ishii KJ; ; Hashiguchi T; Ikeda T; Saito A; Fukuhara T; Tanaka S; Matsuno K; Sato K
Cell; 2022 Oct; 185(21):3992-4007.e16. PubMed ID: 36198317
[TBL] [Abstract][Full Text] [Related]
14. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa.
Sun K; Tempia S; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; Carrim M; Martinson NA; Kahn K; Lebina L; du Toit JD; Mkhencele T; Viboud C; Cohen C;
Nat Commun; 2023 Jan; 14(1):246. PubMed ID: 36646700
[TBL] [Abstract][Full Text] [Related]
15. Raman Fingerprints of SARS-CoV-2 Omicron Subvariants: Molecular Roots of Virological Characteristics and Evolutionary Directions.
Pezzotti G; Ohgitani E; Fujita Y; Imamura H; Pappone F; Grillo A; Nakashio M; Shin-Ya M; Adachi T; Yamamoto T; Kanamura N; Marin E; Zhu W; Inaba T; Tanino Y; Nukui Y; Higasa K; Yasukochi Y; Okuma K; Mazda O
ACS Infect Dis; 2023 Nov; 9(11):2226-2251. PubMed ID: 37850869
[TBL] [Abstract][Full Text] [Related]
16. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants.
Qu P; Evans JP; Kurhade C; Zeng C; Zheng YM; Xu K; Shi PY; Xie X; Liu SL
mBio; 2023 Feb; 14(1):e0317622. PubMed ID: 36625591
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Omicron variants BA.4 and BA.5 dominated the fifth COVID-19 epidemiological wave in Mexico.
Taboada BI; Zárate S; García-López R; Muñoz-Medina JE; Gómez-Gil B; Herrera-Estrella A; Sanchez-Flores A; Salas-Lais AG; Roche B; Martínez-Morales G; Domínguez Zárate H; Duque Molina C; Avilés Hernández R; López S; Arias CF
Microb Genom; 2023 Dec; 9(12):. PubMed ID: 38112714
[TBL] [Abstract][Full Text] [Related]
18. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa.
Sun K; Tempia S; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; Carrim M; Martinson NA; Kahn K; Lebina L; du Toit JD; Mkhencele T; Viboud C; Cohen C;
medRxiv; 2022 Aug; ():. PubMed ID: 36032973
[TBL] [Abstract][Full Text] [Related]
19. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
20. Investigation of an international water polo tournament in Czechia as a potential source for early introduction of the SARS-CoV-2 Omicron variant into Belgium, Switzerland and Germany, November 2021.
Rudin C; Bollen N; Hong SL; Wegner F; Politi L; Mellou K; Geenen C; Gorissen S; Verhasselt B; Durkin K; Henin C; Logist AS; Dellicour S; Resa T; Stadler T; Maes P; Cuypers L; André E; Egli A; Baele G
Euro Surveill; 2023 Nov; 28(45):. PubMed ID: 37943503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
